Abstract: This systematic review aims to provide with information for the future clinical trials of human immunodeficiency virus(HIV) preventive vaccine in China on the phaseⅡ/Ⅲ clinical trials of HIV preventive vaccines worldwide. Related literatures were collected by the joint use of medical subject headings (Mesh) and free terms from Medline. The types of vaccination, research subjects, immunogenicity and the efficacy of the clinical trials were sorted out and analyzed. According to the inclusive and exclusive criteria, total twenty five literatures were selected. There were more and more various types and the strategies of the vaccination with stronger immunogenicity, yet RV144 was the only clinical trial with significant efficacy. Based on the previous worldwide researches' findings, while many types of HIV preventive vaccines have been developed, there is still the need to explore potential candidates for HIV has various mutation, and there are confusions about protective immune response to HIV and pre-immune response to viral vectors effecting the vaccine efficacy. According to the previous experiences, it is necessary to target the local epidemic HIV genotypes, to apply the regimens of multiple vaccines and to investigate the HIV incidence rate, follow-up rate and willing-to-participate rate of high-risk populations in advance if large clinical trials of HIV preventive vaccines will be conducted in China.